On August 4, Cailian Press (editor Pi Fang) reported according to the Choice data that as of the publication, 18 listed companies including Montage Technology, Zhejiang Crystal-optech, Espressif Systems, Lianyong Medical, Shanghai Micro-Port Endovascular MedTech (Group) Co., Ltd., China Resources Boya Bio-pharmaceutical Group, Maiwei Biological-U, Satellite Chemical, Zhongji Innolight, Zhejiang Jolly Pharmaceutical, Shengyi Electronics, Zhejiang Supcon Technology Co., Ltd., Streamax Technology, Inner Mongolia Yuanxing Energy, Huagong Tech, Amlogic, Hundsun Technologies Inc., and Guangdong Haid Group have received more than 160 institutional visits since July 1- August 4. The specific situation is shown in the figure below:

Among them, Lianyong Medical, Shanghai Micro-Port Endovascular MedTech (Group) Co., Ltd., China Resources Boya Bio-pharmaceutical Group, Maiwei Biological-U, and Zhejiang Jolly Pharmaceutical are all in the medical and biological industry, and the number of institutional visits since July is 257, 251, 234, 223, and 207, respectively. Montage Technology, Zhejiang Crystal-optech, Shengyi Electronics and others are also on the list of institutional research in early July. (For specific details, see Cailian Press's in-depth report on July 14: Since July, these listed companies have been "broken through"! Self-driving concept stocks received institutional research, and a list of stocks with high institutional reception visits was revealed.)

On the news, the National Medical Products Administration issued a reply on agreeing to carry out the optimization and innovative drug clinical trial evaluation and approval pilot in Beijing and Shanghai, agreeing to carry out the optimization and innovative drug clinical trial evaluation and approval pilot in Beijing and Shanghai. This means that Beijing and Shanghai have become the first batch of approved cities since the work plan for the pilot project of the optimization and innovative drug clinical trial evaluation and approval was issued. In this year's "Government Work Report," the keyword "innovative drugs" was mentioned for the first time as one of the representatives of "emerging industries." Subsequently, at the national level and in many provinces and cities represented by Beijing, Shanghai, and Guangzhou, relevant innovative drug support policies were intensively introduced. In addition, Wuxi AppTec, the "CXO No.1" has released the first half of the year report on July 29. Although revenue and net profit have both declined, Cailian Press reporters noticed that Wuxi AppTec did not change its annual revenue target. Industry experts told Cailian Press reporters that from the perspective of orders in hand, Wuxi AppTec still has the confidence to achieve its annual revenue target.

The domestic high-end imaging equipment leader, Lianyong Medical, stated in the investor relations activity record table released on July 30 that currently, the Chinese PET/CT market is still in the early stage of development and the overall growth rate will be high in the future. By 2024, the expected PET/CT ownership per million people in China will be close to 0.78 units, and by 2030, the expected PET/CT ownership per million people in China will reach 2.41 units. Based on this, the overall PET/CT market size in China is expected to be about 5.34 billion yuan in 2030, and the compound annual growth rate during the period from 2020 to 2030 will reach about 15.0%.

Lianyong Medical stated that the company has completed the vertical innovation chain of "system-core components-basic components" of molecular imaging, which not only has greater innovation freedom, but also achieved a leap from challenger to leader. According to third-party data, since 2016, Lianyong Medical has ranked first in the newly added market share for eight consecutive years, and the overseas market has also achieved rapid breakthroughs and entered multiple countries, such as the United States, Japan, France, New Zealand, India, and Italy.

Shanghai Microport Endovascular Medtech(Group)Co.,Ltd., which specializes in interventional medical devices for the main artery and peripheral blood vessels, released an announcement on July 1, that it is expected to achieve a net income of CNY 0.391 billion to 0.419 billion in the first half of 2024, an increase of 40%-50% year-on-year. During the reporting period, the company's innovative products, including the Castor branch-type aortic stent graft and delivery system, Minos abdominal aortic stent graft and delivery system, and Reewarm PTX drug balloon dilation catheter continued to exert force, and new products Talos straight tubular thoracic aorta stent graft system and Fontus interventional stent system saw increases in the number of admissions and terminal implants.

On the same day, Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. announced that it intends to acquire 72.37% equity of Optimum Medical Device Inc. for $65 million. At an overseas major merger and acquisition progress communication conference call on July 2, Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. said that in March 2022, it invested in OMD, with an investment amount of $21 million and a 27.632% stake. The post-investment valuation was $76 million. This acquisition is a purchase of the total 72.368% stake held by Earl Intellect Limited and Turbo Heart Limited by the overseas subsidiary of Shanghai Microport Endovascular Medtech (Group) Co., Ltd. After the acquisition, Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. will hold 100% equity. OMD has gradually achieved a balance of profits and losses, and the acquisition of OMD is expected to have a positive impact on the company's operating performance based on its future profit expectations. Shanghai Microport Endovascular Medtech(Group)Co.,Ltd. said that through this transaction, it will help strengthen the company's synergy in research and development, production, and sales of interventional medical devices for the main artery, as well as increase the innovation and R&D strength of the company's aortic vascular stent and other products.

China Resources Boya Bio-Pharmaceutical Group, which is a designated unit engaged in blood product production, announced on July 17 that in order to expand the blood product business, the company plans to acquire 100% equity of Green Cross Hong Kong Holdings Co., Ltd. held by GCCorp., Synaptic and individual sellers for CNY 1.82 billion, thereby indirectly acquiring Green Cross (China) Bio-Products Co., Ltd., a blood product main body in China. After the completion of the transaction, the company will wholly own a blood product production enterprise, add a production license, add four operating single plasma collection stations, and add plasma stations in two provincial regions.

Later, during the conference call on July 18, China Resources Boya Bio-Pharmaceutical Group responded to the question, "how is the operation of the target assets planned for the next few years?" The company stated that the short-term period will improve significantly, and financial statements will change significantly after clearing and terminating related transactions; in the medium term, the regeneration rate will improve, and tonnage output will increase significantly. In the medium and long term, with the synergies and empowerment of management experience between the company and the target company, the plasma station's plasma collection capacity, personnel effectiveness, and tonnage income will significantly improve. In addition, China Resources Boya Bio-Pharmaceutical Group also stated that after the completion of the transaction, the company will plan the product structure, output existing process technology, explore yield improvement and process optimization, and also consider providing guarantees for future new product development to comprehensively improve the utilization rate of tons of plasma. The company and Green Cross China will form a complementary advantage through technical cooperation to improve the generation rate of their respective products and achieve efficiency gains for both licenses.

MabWay Pharmaceutical Co., Ltd. is an innovative biopharmaceutical company that focuses on antibody drugs. In the research information announcement released on July 22, MabWay Pharmaceutical Co., Ltd. stated that it achieved a series of significant progress in the Nectin-4ADC project this year. In March, the results were presented orally in the SGO (Society of Gynecologic Oncology) and in June, the results were presented orally in ASCO (American Society of Clinical Oncology). The company plans to launch 1-2 new ADC drugs into clinical trials within the next year. The company is very cautious when selecting molecules for development, values global differentiated leading advantages, and tends to select newer targets or products with better competition.

On July 12th, analyst Wu Yunfei from Orient Securities wrote a research report saying that MabWay Pharmaceutical Co., Ltd. currently have three approved products on the market: Adalimumab biosimilar (Junmaikang), Denosumab biosimilar (osteoporosis field, Mailishu) and Denosumab biosimilar (tumor bone metastasis field, Maiweijian). The commercial sales of the newly approved product, Maiweijian, and the continuous volume of Junmaikang and Mailishu are the main contributors to the significant increase in revenue in 2024.

Zhejiang Jolly Pharmaceutical Co., Ltd. is based on the production of traditional Chinese medicine products using medicinal fungus biotechnology to achieve industrialized production of the rare Chinese herbal medicine Wulingzhi. Jolly Pharmaceutical released its semi-annual report on July 29, which showed that its revenue for the first half of this year was CNY 1.428 billion, a year-on-year increase of 41.21%, its net income was CNY 0.296 billion, a year-on-year increase of 49.78%. Jolly Pharmaceutical stated that during the reporting period, the sales of its Wuling capsule and Lingze tablet continued to grow well; due to the significant increase in the sales of Chinese medicine netted medicinal pieces on the hospital Internet in June, the sales revenue of Chinese medicine pieces increased significantly compared to the same period last year; the sales revenue of Chinese medicine formula granules increased significantly compared to the previous year due to the increase in the number of recorded varieties.

In the research announcement released on August 1st by Zhejiang Jolly Pharmaceutical, it stated that with the increasing demand for traditional Chinese medicine health and wellness, the market for traditional Chinese medicine tea beverages, such as Wu Mei Tang, was hotly sought after in the second quarter of this year. The sales of its traditional Chinese medicinal slices on the hospital's internet platform sharply increased, and the sales revenue of the traditional Chinese medicine slice series grew significantly compared to the same period last year. Sales of its traditional Chinese medicine tea beverages are mainly in the second quarter, and accounts receivable are all within the account period, resulting in a significant increase in accounts receivable. The traditional Chinese medicinal slice business of the company has stable growth every year. With the gradual improvement of the scale benefits and brand effect of the traditional Chinese medicinal slices, and the increasingly close cooperation with large hospitals, the company will continue to deeply cultivate the domestic market and further strengthen market development, and strive to increase the market share of traditional Chinese medicinal slices in Zhejiang Province in the future.